Connect with us

Legal & Regulation

Curaleaf Products to be Pulled from CVS Shelves Due to of FDA Warning

Published

on

Curaleaf Products to be Pulled from CVS Shelves Due to of FDA Warning

Curaleaf, a CBD company based in Massachusetts, received a warning letter from the Food and Drug Administration concerning the company’s sale of CBD products claiming to treat serious health issues.

The Agency also issued a press announcement on the warning letter, stating that the company received a warning letter,

“for illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products treat cancer, Alzheimer’s disease, opioid withdrawal, pain and pet anxiety, among other conditions or diseases.”

The announcement also indicates that FDA Commissioner Ned Sharpless, M.D. stated,

“Selling unapproved products with unsubstantiated therapeutic claims — such as claims that CBD products can treat serious diseases and conditions — can put patients and consumers at risk by leading them to put off important medical care. Additionally, there are many unanswered questions about the science, safety, effectiveness and quality of unapproved products containing CBD.”

It appears that the letter is already having repercussions on Curaleaf. Reportedly, CVS will be pulling some of Curaleaf’s products from its shelves. The FDA letter touched upon several of Curleaf’s products, such as lotions, pain relief patches, vape pens, and tinctures.

Mike DeAngelis, CVS’s Senior Director indicated, “Following the FDA’s warning letter to Curaleaf, we will be removing these items from our CBD offering.” He added, “At this time, we have no plans to resume selling these products once they are removed from our stores.”

Per the letter, Curaleaf has 15 days to respond to the FDA. Curaleaf indicated in a statement that the letter is currently under review and that,

“We can reaffirm that nothing in the letter raises an issues concerning the safety of any Curaleaf product. Curaleaf products are all derived from hemp and meet the requirements of the Farm Bill.”

All information is for general informational and educational purposes only. Nothing should be interpreted as legal or wellness advice.

Jane is a regular contributor who learned about the great benefits of CBD a few years ago after starting it herself. Impressed by its effects, she's interested in helping others learn about options that can be helpful for them.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com

Copyright © 2020 TimesofCBD.com | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.